



Rachel Sher
Vice President, Policy and Regulatory Affairs

Rachel Sher joined the National Organization for Rare Disorders (NORD) in 2019 as Vice President, Policy and Regulatory Affairs, based in the Washington, DC office. Rachel brings nearly 20 years of experience in federal health policy. Prior to joining NORD, Rachel served as Senior Policy Analyst in the Commissioner’s Office of Policy at the US Food and Drug Administration (FDA) where she acted as the FDA lead in the 21st Century Cures Act legislative process.

For ten years before joining FDA, Rachel served as Senior FDA Counsel for Ranking Member (Formerly Chairman) Henry A. Waxman, the leading author of the 1983 Orphan Drug Act, both on the Democratic Committee Staff for the Energy and Commerce Committee and in Representative Waxman’s personal office. Just prior to joining NORD, Rachel served as Deputy General Counsel at the Association for Accessible Medicines. She holds degrees from the University of Florida Levin College of Law (JD), The George Washington University School of Public Health (MPH) and Duke University (BA). Rachel brings this breadth of expertise to leading NORD’s strategy for engaging policymakers at the federal and state levels in an effort to effect positive change for the rare disease community.

1779 MASSACHUSETTS AVENUE NW, SUITE 500
WASHINGTON, DC 20036
T 202-588-5700 ■ F 202-588-5701

55 KENOSIA AVENUE
DANBURY, CT 06810
T 203-744-0100 ■ F 203-263-9938

1900 CROWN COLONY DRIVE, SUITE 310
QUINCY, MA 02169
T 617-249-7300 ■ F 617-249-7301

rarediseases.org ■ orphan@rarediseases.org

NORD® and icon are registered trademarks of the National Organization for Rare Disorders. NORD is a registered 501(c)(3) charity organization.